Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effect of Toothpaste on the Reduction of Plaque and Inflammation

5 februari 2016 bijgewerkt door: Katrin Lorenz, Technische Universität Dresden

Clinical Evaluation of the Effect of an Experimental Toothpaste on the Reduction of Dental Plaque and Gingival Inflammation

The purpose of this double blind study is to prove whether a fluoride containing toothpaste is able to reduce dental plaque and gingival inflammation in patients who have gingivitis when applied twice daily during brushing at home over a period of 12 weeks.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Before study start, investigators and study nurses will be trained on how to apply SOPs, parameters, and adverse event management. On-site monitoring will be done by the sponsor after recruitment, after visit 2 and after the final visit.

All source data will be entered in paper CRFs. For the statistical analysis these data will be entered into the data bank via double data entry. Programmed range checks, validity checks, consistency checks, and manual/visual data checks for medicinal plausibility will be done before the blind data review meeting. During blind data review meeting minor protocol violations will be recorded and assessed. No imputation of missing data will be done for ITT or PP analyses.

The sample size estimation was carried out by means of one-sided unpaired t-test with a one-sided significance level of α=0.05. For testing superiority of the test product over negative control, the investigators test the hypothesis, H0: μTest product - μNegative control ≤ 0 H1: μTest product - μNegative control > 0 by using a one-sided t-test with α=0.05. A relevant difference of Δ=0.14 and a standard deviation of σ=0.4 was assumed based on previous studies. When estimating a drop-out rate of about 20 % a total of 120 = 102 + 18 subjects per group will be assigned at study start. Drop-outs will not be replaced during the study.

The primary parameter is the difference of plaque index between baseline (V1) value and the value after 12 weeks +/- 5 days (V3) of product use. For primary statistical analysis, a t-tests (unpaired situation) will be performed at a one-sided significance level of α=0.05. The primary efficacy analysis will be performed on the ITT-analysis set.

Secondary variables will be assessed with t-tests and confidence intervals to compare differences between V2, V3, and baseline for test product group and negative control group. Descriptive statistics will be performed for oral examinations for each group (counts and percentages of scores for nominal and ordinal scaled data, for at least ordinal scaled data minimum, maximum, median, mean value and standard deviation).

A two-sided significance level of α=0.05 is chosen for all secondary analyses, no adjustment for multiplicity will be done. Safety assessments will be based mainly on the frequency of adverse events.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

241

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Duitsland
      • Dresden, Duitsland, 01307
        • Technische Universität Dresden

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Male and female adults (aged 18 to 65 years),
  • Individuals with gingival inflammation, mean full-mouth GI ≥ 1.2 at inclusion,
  • Individuals with plaque, mean full-mouth PI ≥ 1.2 at inclusion,
  • Non-smokers or former smokers for at least 1 year or occasional smokers with a maximum of 5 cigarettes per week,
  • Individuals who have at least 20 own teeth excluding the wisdom teeth,
  • Subjects must have read, understood and signed the informed consent form
  • Willingness to abstain from use of interdental brushing devices that contain antibacterial agents, like amine fluoride, chlorhexidine, silver ions etc. during the full course of the study

Exclusion Criteria:

  • Individuals who have severe systemic diseases (tumors, infectious diseases) and diseases that require regular systemic medication intake that may affect the gingival condition (e. g. phenytoin, nifedipine, cyclosporine, antibiotics, steroids, antiphlogistics)
  • Individuals who have moderate and severe chronic or aggressive periodontitis (PSI > 2 in more than 2 sextants or PSI > 3),
  • Individuals who require antibiotic treatments for dental appointments (endocarditis prophylaxis), Individuals treated with antibiotics less than 8 weeks prior to the baseline examination and/or during the duration of the trial,
  • Individuals who have participated in another clinical study less than 4 weeks prior to the baseline examination,
  • Individuals who have mucosal diseases,
  • Individuals who have severe oro-pharyngeal infections,
  • Individuals who have significant dental disorders (e.g.: caries, suspected pulp pathology, abscess, pulpitis),
  • History of gingival surgery in the previous three month,
  • Ongoing dental treatment or any other medical treatment of the oral cavity,
  • Individuals who are pregnant or breast feeding,
  • Individuals with a history of chronic drug abuse or another illness which does not allow the person to assess the nature and/or possible consequences of the study,
  • Smokers with more than 5 cigarettes per week,
  • Individuals with known hypersensitivity or allergy to the test products and its ingredients,
  • Individuals who were treated with antibacterial mouthrinses (e. g. chlorhexidine) 4 weeks or less before recruitment,
  • Individuals unwilling to abstain from additional oral hygiene measures during the treatment phase with exception of their habitual mechanical cleaning procedures,
  • Non-Caucasians,
  • Subjects can be excluded at the principal investigators discretion.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Test group
Amine fluoride toothpaste
Ander: Amine fluoride
toothpaste
Placebo-vergelijker: Control group
Placebo Sodium monofluorophosphate toothpaste
Ander: Placebo
toothpaste
Andere namen:
  • Sodium monofluorophosphate

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Plaque index (Silness and Loe 1964)
Tijdsspanne: Change in plaque index from baseline at 12 weeks
Difference of plaque index, compared between test group and control group.
Change in plaque index from baseline at 12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Plaque index (Silness and Loe 1964)
Tijdsspanne: Change in plaque index from baseline at 3 weeks
Difference of plaque index, compared between test group and control group.
Change in plaque index from baseline at 3 weeks
Plaque index (Silness and Loe 1964)
Tijdsspanne: Change in plaque index from week 3 at 12 weeks
Difference of plaque index, compared between test group and control group.
Change in plaque index from week 3 at 12 weeks
Gingival Index (Loe 1967)
Tijdsspanne: Change in gingival index from baseline at 3 weeks
Difference of gingival index, compared between test group and control group.
Change in gingival index from baseline at 3 weeks
Gingival Index (Loe 1967)
Tijdsspanne: Change in gingival index from baseline at 12 weeks
Difference of gingival index, compared between test group and control group.
Change in gingival index from baseline at 12 weeks
Gingival Index (Loe 1967)
Tijdsspanne: Change in gingival index from 3 weeks at week 12
Difference of gingival index, compared between test group and control group.
Change in gingival index from 3 weeks at week 12
Modified Sulcus Bleeding Index (Muhlemann and Son 1971):
Tijdsspanne: Change in bleeding index from baseline at 12 weeks
Difference of bleeding index, compared between test group and control group.
Change in bleeding index from baseline at 12 weeks
Modified Sulcus Bleeding Index (Muhlemann and Son 1971):
Tijdsspanne: Change in bleeding index from baseline at week 3
Difference of bleeding index, compared between test group and control group.
Change in bleeding index from baseline at week 3
Modified Sulcus Bleeding Index (Muhlemann and Son 1971):
Tijdsspanne: Change in bleeding index from week 3 at week 12
Difference of bleeding index, compared between test group and control group.
Change in bleeding index from week 3 at week 12
Adverse events
Tijdsspanne: up to 12 weeks from baseline
List all
up to 12 weeks from baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Technische Universität Dresden

Medewerkers

Colgate Palmolive

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 september 2015

Primaire voltooiing (Werkelijk)

1 februari 2016

Studie voltooiing (Werkelijk)

1 februari 2016

Studieregistratiedata

Eerst ingediend

3 september 2015

Eerst ingediend dat voldeed aan de QC-criteria

16 september 2015

Eerst geplaatst (Schatting)

17 september 2015

Updates van studierecords

Laatste update geplaatst (Schatting)

8 februari 2016

Laatste update ingediend die voldeed aan QC-criteria

5 februari 2016

Laatst geverifieerd

1 februari 2016

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • PAR012015

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren